Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

This study has been completed.

Sponsor:

Information provided by:

Rigshospitalet, Denmark

ClinicalTrials.gov Identifier:

NCT00286351

First received: February 1, 2006

Last updated: April 20, 2007

Last verified: April 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

February 1, 2006

Last Updated Date

April 20, 2007

Start Date ^ICMJE

January 2005

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

size of endometriomas after 2½ month of combined downregulation

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT00286351 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

Official Title ^ICMJE

Not Provided

Brief Summary

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Phase 4

Study Design ^ICMJE

Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Condition ^ICMJE

Endometriosis

Intervention ^ICMJE

Drug: Combined treatment with Arimidex and Zoladex before IVF

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
Couples with indication and wish for IVF/ICSI
Age of women: 20-40 years
Regular menstrual cycle within normal range (21-35 days)
Body Mass Index (BMI): 18-30 kg/m2

Exclusion Criteria:

History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
Treatment of endometriosis with GnRH agonist during the last 3 month

Gender

Female

Ages

20 Years to 40 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Denmark

Administrative Information

NCT Number ^ICMJE

NCT00286351

Other Study ID Numbers ^ICMJE

endo 220604

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Rigshospitalet, Denmark

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Kristine Lossl, medical doctor

The Fertility Clinic, Copenhagen University Hospital Rigshospitalet

Information Provided By

Rigshospitalet, Denmark

Verification Date

April 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top